Beam Therapeutics Inc
NASDAQ:BEAM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (25), the stock would be worth $34.4 (27% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 19.7 | $27.11 |
0%
|
| 3-Year Average | 25 | $34.4 |
+27%
|
| 5-Year Average | 32.7 | $44.86 |
+65%
|
| Industry Average | 6.7 | $9.25 |
-66%
|
| Country Average | 2.4 | $3.35 |
-88%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$2.8B
|
/ |
Jan 2026
$139.7m
|
= |
|
|
$2.8B
|
/ |
Dec 2026
$48.4m
|
= |
|
|
$2.8B
|
/ |
Dec 2027
$64.7m
|
= |
|
|
$2.8B
|
/ |
Dec 2028
$126.4m
|
= |
|
|
$2.8B
|
/ |
Dec 2029
$384.4m
|
= |
|
|
$2.8B
|
/ |
Dec 2030
$821.9m
|
= |
|
|
$2.8B
|
/ |
Dec 2031
$1B
|
= |
|
|
$2.8B
|
/ |
Dec 2032
$1.3B
|
= |
|
|
$2.8B
|
/ |
Dec 2033
$1.8B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Beam Therapeutics Inc
NASDAQ:BEAM
|
2.8B USD | 19.7 | -34.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 5.7 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 5 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 5.5 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 9.1 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 5.5 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 11.6 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 2.8 | 31.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Beam Therapeutics Inc
Glance View
Beam Therapeutics Inc. stands at the cutting edge of the biotechnology sector, pioneering the fascinating realm of gene editing through its unique approach known as base editing. Conceived from the intellectual explorations of world-renowned scientists, Beam Therapeutics intertwines science and innovation to redesign the genetic fabric that defines life. Unlike traditional gene-editing techniques that involve breaking the DNA strands, Beam’s base editing is precise and subtle, modifying individual letters of the genetic code without introducing double-stranded breaks. This precision technology has significant implications, offering potential treatments for a spectrum of genetic disorders that have long eluded medical science. The company’s business model is intricately linked to the commercialization of its novel base editing platforms and the development of therapeutic candidates targeting critical genetic diseases. By strategically partnering with pharmaceutical giants, Beam Therapeutics leverages its cutting-edge technology to stimulate revenue streams through collaborations and licensing agreements. Additionally, the company aims to navigate the complex pathways of regulatory approval, advancing its drug candidates from laboratory research through clinical trials towards eventual market rollouts. As such, Beam Therapeutics is not merely focused on scientific discovery but is equally committed to transforming these breakthroughs into viable products that can, one day, redefine the clinical landscape of genetic medicine.
